 |
||
|
|
Hypertension Diagnostics Announces FY 2007 Second Quarter Results ST. PAUL, MN – February 14, 2006 – Hypertension Diagnostics, Inc. (OTC: HDII.OB), today announced financial results for the second quarter of fiscal year 2007 ended December 31, 2006. Revenue for the quarter totaled $548,723 compared to $541,106 in the prior year’s second quarter ended December 31, 2005. However, in the prior year’s second quarter, the Company’s sales benefited from a $135,000 sale to an international distributor which did not recur in this year’s second quarter. Excluding the international sales results in the prior year, the $548,723 of sales in the current quarter are up 26% from the adjusted results in the prior year’s quarter. The Company incurred a net loss of $225,404 for the current quarter or $(.01) per share compared with a net loss of $283,927 for the prior year’s quarter or $(.01) per share. Included in the net loss of $225,404 for the quarter are total non-cash charges (expenses associated mainly with stock compensation, depreciation, stock options) of $166,072. The Company reported a cash balance of $1,441,378 on December 31, 2006. For the six month period ended December 31, 2006, total revenue was $971,208, compared to $922,022 for the same period one year ago, a 5.3% increase. For the six month period ended December 31, 2006, the Company incurred a net loss of $413,485, or $(.01) per share, compared with a net loss of $621,144, or $(.02) per share, for the same period one year ago.
“We are extremely pleased with the financial results for the quarter,
which are among the strongest quarterly results that the Company has
seen in recent years,” said Mark N. Schwartz, Chairman and CEO. “The
prior year’s quarter had the benefit of an international shipment and
four full time sales reps, while the current quarter consisted totally
of domestic sales and the Company only had three full time sales reps,
two of whom have been with the Company less than six months. We believe
these results provide evidence of the fact that the Company can identify
and develop new markets quickly, an important component to our future
growth,” commented Schwartz. |
|
|
Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not a prediction of actual future results. Actual results could differ materially from those presented and anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company’s 2006 Annual Report on Form 10-KSB, and subsequent Quarterly Reports on 10-QSB, all of which were filed with the U.S. Securities and Exchange Commission, as well as others not now anticipated.
CVProfilor is a registered trademark of Hypertension Diagnostics, Inc. Hypertension Diagnostics, HDI/PulseWave, PulseWave and CVProfile are trademarks of Hypertension Diagnostics, Inc. All rights reserved.
Website: www.HDII.com Return to the Main HDI Newsroom 
|
||
|
Copyright © 2007 Hypertension Diagnostics, Inc |
||
